Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation

American Journal of Transplantation

Volumn 14, Issue 12, 2014, Pages 2736-2748

  Vos, R ^a   Verleden, S E ^a   Ruttens, D ^a   Vandermeulen, E ^a   Bellon, H ^a   Neyrinck, A ^a   Van Raemdonck, D E ^a   Yserbyt, J ^a   Dupont, L J ^a   Verbeken, E K ^a   Moelants, E ^a   Mortier, A ^a   Proost, P ^a   Schols, D ^b   Cox, B ^c   Verleden, G M ^a   Vanaudenaerde, B M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

acute; bronchoalveolar lavage (BAL); Clinical research; dysfunction; immune regulation; immunobiology; immunosuppressant; lung (allograft) function; lung transplantation; other; practice; pulmonology; rejection; science; translational research

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; C REACTIVE PROTEIN; CYCLOSPORIN A; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR BB; PROTON PUMP INHIBITOR; RANTES; TACROLIMUS; VASCULOTROPIN; ANTIINFECTIVE AGENT; CYTOKINE;

ADULT; AGED; ARTICLE; BACTERIAL GROWTH; BIOPSY; BRONCHIOLITIS; BRONCHITIS; CANDIDA ALBICANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENTEROBACTER CLOACAE; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTIONAL EXHALED NITRIC OXIDE; GASTROESOPHAGEAL REFLUX; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HISTOLOGY; HUMAN; KLEBSIELLA PNEUMONIAE; LAMINA PROPRIA; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTOSIS; LUNG FLUID; LUNG FUNCTION; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPHOCYTIC AIRWAY INFLAMMATION; LYMPHOCYTIC BRONCHIOLITIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPHIL COUNT; NEUTROPHILIA; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; RESPIRATORY AIRFLOW; RESPIRATORY TRACT INFLAMMATION; SERRATIA MARCESCENS; SPIROMETRY; TREATMENT DURATION; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; COMPLICATION; DRUG EFFECTS; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; INTERVENTION STUDY; LUNG DISEASES; LUNG FUNCTION TEST; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PATHOLOGY; PNEUMONIA; POSTOPERATIVE COMPLICATION; PROGNOSIS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHITIS; BRONCHOALVEOLAR LAVAGE; C-REACTIVE PROTEIN; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INTERVENTION STUDIES; LUNG DISEASES; LUNG TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; PNEUMONIA; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SPIROMETRY; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84910665403     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12942     Document Type: Article

References (58)

1. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA., Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008; 177: 1033-1040.
2. Greenland JR, Jones KD, Hays SR, et al. Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2013; 187: 417-423.
3. Tavora F, Drachenberg C, Iacono A, Burke AP., Quantitation of T lymphocytes in posttransplant transbronchial biopsies. Hum Pathol 2009; 40: 505-515.
4. Abernathy EC, Hruban RH, Baumgartner WA, Reitz BA, Hutchins GM., The two forms of bronchiolitis obliterans in heart-lung transplant recipients. Hum Pathol 1991; 22: 1102-1110.
5. Ryu JH, Myers JL, Swensen SJ., Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168: 1277-1292.
6. Belperio JA, Weigt SS, Fishbein MC, Lynch JP III., Chronic lung allograft rejection: Mechanisms and therapy. Proc Am Thorac Soc 2009; 6: 108-121.
7. Yousem SA., The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995; 26: 668-675.
8. Tiriveedhi V, Takenaka M, Ramachandran S, et al. T regulatory cells play a significant role in modulating MHC class I antibody-induced obliterative airway disease. Am J Transplant 2012; 12: 2663-2674.
9. Milne DS, Gascoigne AD, Wilkes J, et al. MHC class II and ICAM-1 expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation 1994; 57: 1762-1766.
10. Angaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 2013; 74: 1478-1485.
11. Verleden SE, Vos R, Vandermeulen E, et al. Involvement of interleukin-17 during lymphocytic bronchiolitis in lung transplant patients. J Heart Lung Transplant 2013; 32: 447-453.
12. Vanaudenaerde BM, Dupont LJ, Wuyts WA, et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006; 27: 779-787.
13. Basha HI, Ramachandran S, Tiriveedhi V, et al. Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by Anti-MHC I antibodies. Transplantation 2013; 95: 293-300.
14. Shilling RA, Wilkes DS., Role of Th17 cells and IL-17 in lung transplant rejection. Semin Immunopathol 2011; 33: 129-134.
15. Vanaudenaerde BM, Verleden SE, Vos R, et al. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am J Respir Crit Care Med 2011; 183: 977-986.
16. Fan L, Benson HL, Vittal R, et al. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am J Transplant 2011; 11: 911-922.
17. Al-Muhsen S, Letuve S, Vazquez-Tello A, et al. Th17 cytokines induce pro-fibrotic cytokines release from human eosinophils. Respir Res 2013; 14: 34.
18. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2008; 8: 1911-1920.
19. Zhao XY, Xu LL, Lu SY, Huang XJ., IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol 2011; 41: 514-526.
20. Chambers DC, Hodge S, Hodge G, et al. A novel approach to the assessment of lymphocytic bronchiolitis after lung transplantation-transbronchial brush. J Heart Lung Transplant 2011; 30: 544-551.
21. Eiwegger T, Gruber S, Geiger C, et al. Impact of systemic immuno-suppression after solid organ transplantation on allergen-specific responses. Allergy 2011; 66: 271-278.
22. Verleden SE, Scheers H, Nawrot TS, et al. Lymphocytic bronchiolitis after lung transplantation is associated with daily changes in air pollution. Am J Transplant 2012; 12: 1831-1838.
23. Tsai HC, Velichko S, Hung LY., Wu R., IL-17A and Th17 cells in lung inflammation: An update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clin Dev Immunol 2013; 2013: 267971.
24. Li N, Harkema JR, Lewandowski RP, et al. Ambient ultrafine particles provide a strong adjuvant effect in the secondary immune response: Implication for traffic-related asthma flares. Am J Physiol Lung Cell Mol Physiol 2010; 299: L374-L383.
25. Gordon IO, Bhorade S, Vigneswaran WT, Garrity ER, Husain AN., SaLUTaRy: Survey of lung transplant rejection. J Heart Lung Transplant 2012; 31: 972-979.
26. De Soyza A, Fisher AJ, Small T, Corris PA., Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am J Respir Crit Care Med 2001; 164: 1209-1212.
27. Ross DJ, Marchevsky A, Kramer M, Kass RM., " Refractoriness" of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant 1997; 16: 832-838.
28. McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089-4097.
29. Vanaudenaerde BM, Wuyts WA, Geudens N, et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007; 7: 76-82.
30. Vos R, Vanaudenaerde BM, Verleden SE, et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 2012; 94: 101-109.
31. Glanville AR., Bronchoscopic monitoring after lung transplantation. Semin Respir Crit Care Med 2010; 31: 208-221.
32. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229-1242.
33. Yousem SA., Lymphocytic bronchitis/bronchiolitis in lung allograft recipients. Am J Surg Pathol 1993; 17: 491-496.
34. Wuyts A, Govaerts C, Struyf S, et al. Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur J Biochem 1999; 260: 421-429.
35. Gijsbers K, Van Assche G, Joossens S, et al. CXCR1-binding chemokines in inflammatory bowel diseases: Down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol 2004; 34: 1992-2000.
36. Van den Steen PE, Husson SJ, Proost P, Van Damme J, Opdenakker G., Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun 2003; 310: 889-896.
37. Menten P, Proost P, Struyf S, et al. Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon-alpha/beta and interferon-gamma reveals MCP-3 heterogeneity. Eur J Immunol 1999; 29: 678-685.
38. Standardization of spirometry, 1994 update: American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
39. Kharitonov SA, Alving K, Barnes PJ., Exhaled and nasal nitric oxide measurements: Recommendations. Eur Respir J 1997; 10: 1683-1693.
40. Verleden GM, Dupont LJ, Van Raemdonck DE, Vanhaecke J, Leuven Lung Transplant Group. Accuracy of exhaled nitric oxide measurements for the diagnosis of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 78: 730-733.
41. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
42. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164-172.
43. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: Divide and conquer ? J Heart Lung Transplant 2010; 29: 1358-1368.
44. de Jong PA, Vos R, Verleden GM, Vanaudenaerde BM, Verschakelen JA., Thin-section computed tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction. Eur Radiol 2011; 21: 2466-2474.
45. Vos R, Vanaudenaerde BM, Verleden SE, et al. Bronchoalveolar lavage neutrophilia in acute lung allograft rejection and lymphocytic bronchiolitis. J Heart Lung Transplant 2010; 29: 1259-1269.
46. Belperio JA, Keane MP, Burdick MD., et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. Immunology 2002; 169: 1037-1049.
47. Shino MY, Weigt SS, Li N, et al. CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction. Am J Respir Crit Care Med 2013; 188: 1117-1125.
48. Asano T, Ogushi F, Tani K, Tamiya H, Nishioka Y, Sone S., Increased macrophage inflammatory protein-1alpha and -1beta in BAL fluid of bronchiolitis obliterans organizing pneumonia. Respirology 2003; 8: 461-466.
49. Jonigk D, Merk M, Hussein K, et al. Obliterative airway remodeling: Molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol 2011; 178: 599-608.
50. Kim TK, St John LS, Wieder ED, Khalili J, Ma Q, Komanduri KV., Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production. J Immunol 2009; 183: 6167-6174.
51. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW., Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 2010; 184: 4215-4227.
52. Donckier V, Craciun L, Miqueu P, et al. Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin. Transplantation 2013; 96: 306-315.
53. Kondo T, Takata H, Matsuki F, Takiguchi M., Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. Immunology 2009; 182: 1794-1798.
54. Conroy DM, Williams TJ., Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res 2001; 2: 150-156.
55. Wuyts WA, Vanaudenaerde BM, Dupont LJ, Demedts MG, Verleden GM., Modulation by cAMP of IL-1beta-induced eotaxin and MCP-1 expression and release in human airway smooth muscle cells. Eur Respir J 2003; 22: 220-226.
56. Sato E, Nelson DK, Koyama S, Hoyt JC, Robbins RA., Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro. Antimicrob Agents Chemother 2001; 45: 401-406.
57. Yousem SA., Graft eosinophilia in lung transplantation. Hum Pathol 1992; 23: 1172-1177.
58. Federica M, Nadia S, Monica M, et al. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection. Clin Transplant 2011; 25: E381-E389.